SOHONOS DIN 02524643
Status: Marketed
Holder: IPSEN BIOPHARMACEUTICALS CANADA INC
Available to quote
Health Canada record
| Active ingredient(s) | PALOVAROTENE 2.5 MG |
|---|
| Dosage form | Capsule |
|---|
| Route | Oral |
|---|
| Schedule | PRESCRIPTION |
|---|
| Class | Human |
|---|
| ATC | M09AX11 PALOVAROTENE |
|---|
| Original market date | 20-Jun-2022 |
|---|
| Current status date | 20-Jun-2022 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
Ipsen Biopharmaceuticals Canada Inc — licence 102222, currently licensed, last inspection rating C (2024-05-06).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing PALOVAROTENE
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02524627 | SOHONOS | IPSEN BIOPHARMACEUTICALS CANADA INC | Capsule | PALOVAROTENE 1 MG | Marketed |
| 02524635 | SOHONOS | IPSEN BIOPHARMACEUTICALS CANADA INC | Capsule | PALOVAROTENE 1.5 MG | Marketed |
| 02524651 | SOHONOS | IPSEN BIOPHARMACEUTICALS CANADA INC | Capsule | PALOVAROTENE 5 MG | Marketed |
| 02524678 | SOHONOS | IPSEN BIOPHARMACEUTICALS CANADA INC | Capsule | PALOVAROTENE 10 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 27451 | 2022-01-21 | New Drug Submission (NDS) | |
Request a quote for SOHONOS
How to read a Canadian DIN record